The Strategie Of Gaining The Most Effective Price For Your Quisinostat

One hundred patients (63.2%) were older than 60 years. In total, 102 patients (64.5%) had advanced disease (including stage III and IV), and 72 patients (45.4%) had Quisinostat in vivo an ECOG PS above grade 2. Ninety-nine patients (62.6%) had B symptoms, and the LDH level was elevated in 94 patients (59.4%). Forty-two patients experienced relapses that occurred 12 months after R-CHOP therapy (26.5%). Twelve patients (7.5%) achieved complete responses (CRs) after salvage therapy. The median follow-up duration was 32.6 months. During a follow-up period of 36.8 months, the PFS and OS rates were 26.9% and 33.5%, respectively, in the ICE group. The median number of chemotherapy cycles was 4. Table 1 Baseline characteristics of the patients. Risk assessment using aa-IPI There were 23 patients AZD2281 solubility dmso in the low-risk group (0 aa-IPI risk factor). There were 67 patients in the intermediate risk group (1 risk factor), and 76 patients in the high-risk group (2-3 risk factors). Significant differences in PFS and OS were noted between the low- and high-risk groups (PFS, P Hesperadin for PFS and P for OS, Fig. 2A-B). Fig. 2 Comparison of clinical outcomes according to a maximum standardized uptake value (SUVmax) cut-off of 6.0. Prognostic factors affecting clinical outcomes To examine whether clinical outcomes were affected by various prognostic factors (age��65 years, low aa-IPI, SUVmax 12 months, and CR status after salvage therapy), the factors were analyzed regarding their prognostic significance for salvage therapy. In univariate analysis, a low aa-IPI (P 12 months (P =0.025 for PFS, P